Thrombosis News and Research

Latest Thrombosis News and Research

Mount Sinai cardiologist receives AHA/ASA Ron Haddock International Impact Award

The American Heart Association (AHA) has awarded world-renowned cardiologist Dr. Valentin Fuster, MD, PhD, Director of Mount Sinai Heart at The Mount Sinai Medical Center, its prominent American Heart Association/American Stroke Association Ron Haddock International Impact Award.

28 Jun 2013

Orlando Health's clinicians provide hospital-level care in patient's home

Instead of admitting patients to medical units at the hospital, clinicians at Orlando Regional Medical Center are providing health care to patients in the comfort of their homes. The new twist on modern medicine is being piloted in a project to provide hospital-level care in a patient's home through home visits, videoconferencing (virtual visit) and telemonitoring (remote vital signs monitoring).

28 Jun 2013

Janssen receives complete response letter from FDA for XARELTO sNDA

Janssen Research & Development, LLC today announced the U.S. Food and Drug Administration has issued a complete response letter for the supplemental New Drug Application for XARELTO (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome.

28 Jun 2013

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Boehringer Ingelheim today announced the submission of an application to the European Medicines Agency (EMA) for use of Pradaxa (dabigatran etexilate) for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE.

24 Jun 2013

Th17 lymphocyte: The master coordinator of cellular inflammation in vessel wall

Every year, more than 16,000 Americans die as a result of what's known as an "aortic dissection" - a catastrophic rupture of the aorta, the body's largest artery. Once thought to be a simple structural failure, aortic dissection is now understood to be caused by an inflammatory process that weakens the artery's walls.

21 Jun 2013

Clinical study shows that clopidogrel not effective in infants with congenital heart diseases

One of the largest clinical trials done in infants with congenital (present at birth) heart diseases, published in the New England Journal of Medicine, shows that the increasingly common practice of using the drug clopidogrel (Plavix-) to reduce shunt-related blood flow issues is not effective in the dose studied.

21 Jun 2013

CLOTS 3 trial demonstrates efficacy of Covidien's Kendall SCD system on immobile stroke patients

Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that an independent study conducted by the University of Edinburgh has successfully demonstrated the effectiveness of Covidien's Kendall SCD™ system with Vascular Refill Detection Technology on immobile stroke patients.

20 Jun 2013

Men with haplogroup I of Y chromosome have 50% greater risk of developing heart disease

University of Leicester scientists have discovered a potential genetic contributor to the increased risk of heart disease among men.

18 Jun 2013

European Commission amends marketing authorisation for Celgene's REVLIMID

Celgene International Sàrl was today notified that the European Commission has amended the marketing authorisation for REVLIMID. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

17 Jun 2013

Study shows patients with avascular necrosis have turned to stem cell therapy for aid

Stem cells have long been touted as the next big thing. Well just maybe, it is here. According to Dr. Dennis Lox, some patients with a disorder of the bone called avascular necrosis (AVN), have turned to stem cell therapy for aid.

15 Jun 2013

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Celgene International Sàrl, a subsidiary of Celgene Corporation today presented results from a randomized, placebo-controlled phase II trial in patients with Behçet's disease at EULAR, the European Congress of Rheumatology annual meeting in Madrid.

14 Jun 2013

ARIAD Pharmaceuticals initiates ponatinib Phase 2 trial in adult patients with metastatic GIST

ARIAD Pharmaceuticals, Inc. today announced the initiation of the Phase 2 trial of Iclusig (ponatinib) in adult patients with metastatic and/or unresectable gastrointestinal stromal tumors.

11 Jun 2013

Abbott starts ABSORB Japan trial to evaluate Absorb BVS in patients with CAD

Abbott today announced that it has initiated the ABSORB Japan randomized controlled clinical trial to evaluate the Absorb Bioresorbable Vascular Scaffold in patients with coronary artery disease, the most common form of heart disease.

11 Jun 2013

Faster, more potent antithrombotic drugs recommended for high-risk heart attack patients

The Cardiovascular Research Laboratory of the Bellvitge Biomedical Research Institute led by the cardiologist of the Bellvitge University Hospital Jos- Luis Ferreiro has conducted a study on the effect of antiplatelet drugs given to high risk patients suffering from acute myocardial infaction (heart attack) in the context of the Infarction Code.

6 Jun 2013

Lupus Foundation of America announces Career Development Award and new summer fellowships

The Lupus Foundation of America, the only national force dedicated to solving the cruel mystery of lupus, announced recipients of five new summer fellowships and the Foundation's first-ever Career Development Award.

3 Jun 2013

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.

3 Jun 2013

New nanoparticle gene delivery method to prevent stenting procedure complications

Stent angioplasty saves lives, but there often are side effects and complications related to the procedure, such as arterial restenosis and thrombosis. In the June 2013 issue of The FASEB Journal, however, scientists report that they have discovered a new nanoparticle gene delivery method that may overcome current limitations of gene therapy vectors and prevent complications associated with the stenting procedure.

1 Jun 2013

OrbusNeich introduces COMBO Dual Therapy Stent

OrbusNeich today launched the world's first dual therapy stent – the COMBO Dual Therapy Stent – to address the challenges of delayed healing of the coronary artery associated with monotherapy drug eluting stents, the current standard of care for the treatment of coronary artery disease.

27 May 2013

Australia's PBAC recommends use of XIFAXAN 550 mg for hepatic encephalopathy

Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic encephalopathy where other treatments have failed or are contraindicated; a potentially life-threatening neuropsychiatric condition associated with liver disease.

24 May 2013

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.

23 May 2013

Thrombosis News and Research

Latest Thrombosis News and Research

Mount Sinai cardiologist receives AHA/ASA Ron Haddock International Impact Award

Orlando Health's clinicians provide hospital-level care in patient's home

Janssen receives complete response letter from FDA for XARELTO sNDA

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Th17 lymphocyte: The master coordinator of cellular inflammation in vessel wall

Clinical study shows that clopidogrel not effective in infants with congenital heart diseases

CLOTS 3 trial demonstrates efficacy of Covidien's Kendall SCD system on immobile stroke patients

Men with haplogroup I of Y chromosome have 50% greater risk of developing heart disease

European Commission amends marketing authorisation for Celgene's REVLIMID

Study shows patients with avascular necrosis have turned to stem cell therapy for aid

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

ARIAD Pharmaceuticals initiates ponatinib Phase 2 trial in adult patients with metastatic GIST

Abbott starts ABSORB Japan trial to evaluate Absorb BVS in patients with CAD

Faster, more potent antithrombotic drugs recommended for high-risk heart attack patients

Lupus Foundation of America announces Career Development Award and new summer fellowships

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

New nanoparticle gene delivery method to prevent stenting procedure complications

OrbusNeich introduces COMBO Dual Therapy Stent

Australia's PBAC recommends use of XIFAXAN 550 mg for hepatic encephalopathy

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Thrombosis News and Research

Latest Thrombosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in